Organon & Co. (NYSE:OGN – Get Free Report) shares reached a new 52-week high on Monday. The stock traded as high as $13.91 and last traded at $13.9050, with a volume of 3,534,006 shares. The stock had previously closed at $13.90.
Analysts Set New Price Targets
Separately, Weiss Ratings upgraded shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $12.00.
View Our Latest Stock Report on Organon & Co.
Organon & Co. Price Performance
The company has a fifty day moving average of $13.77 and a 200-day moving average of $11.76. The firm has a market cap of $3.65 billion, a P/E ratio of 18.31, a P/E/G ratio of 1.28 and a beta of 1.53. The company has a debt-to-equity ratio of 7.11, a current ratio of 2.02 and a quick ratio of 1.51.
Organon & Co. (NYSE:OGN – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.06. Organon & Co. had a net margin of 3.49% and a return on equity of 82.06%. The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.58 billion. On average, sell-side analysts anticipate that Organon & Co. will post 3.24 EPS for the current fiscal year.
Organon & Co. Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Monday, November 9th will be issued a dividend of $0.02 per share. The ex-dividend date is Monday, November 9th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s payout ratio is 10.53%.
Institutional Investors Weigh In On Organon & Co.
Institutional investors have recently added to or reduced their stakes in the company. Pathstone Holdings LLC increased its stake in shares of Organon & Co. by 5.2% in the third quarter. Pathstone Holdings LLC now owns 48,956 shares of the company’s stock worth $671,000 after purchasing an additional 2,441 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of Organon & Co. by 162.0% in the third quarter. Empowered Funds LLC now owns 39,335 shares of the company’s stock worth $539,000 after acquiring an additional 24,323 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in shares of Organon & Co. by 18.4% in the third quarter. Steward Partners Investment Advisory LLC now owns 8,877 shares of the company’s stock worth $122,000 after acquiring an additional 1,379 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Organon & Co. by 0.6% in the third quarter. State Board of Administration of Florida Retirement System now owns 220,182 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,294 shares in the last quarter. Finally, Bleakley Financial Group LLC purchased a new position in shares of Organon & Co. in the third quarter valued at $261,000. 77.43% of the stock is owned by institutional investors.
Organon & Co. Company Profile
Organon & Co. is a global health care company focused on women’s health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women’s health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology.
Recommended Stories
- Five stocks we like better than Organon & Co.
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
